NAD recommends more modifications for Mead Johnson’s Enfamil ads
NEW YORK Although Mead Johnson has said it voluntarily will modify or discontinue certain advertising claims for the infant formula Enfamil Premium with triple health guard, the National Advertising Division of the Council of Better Business Bureaus has recommended additional modifications to print, Web site and broadcast advertising for the product, the division announced Thursday.
NAD, the advertising industry’s self-regulatory forum, examined advertising for the product following a challenge by Abbott Nutrition, the maker of the Similac line of infant formulas.
Claims at issue included:
- Only new Enfamil Premium has triple health guard — clinically proven to promote growth, to improve brain and eye development, and to improve respiratory and immune system outcomes;
- Our new triple health guard is found only in Enfamil Premium. The result of years of leading edge research, new Enfamil Premium is clinically proven to promote growth, improve brain and eye development, and improve respiratory and immune system outcomes; and
- Only NEW immunity building Enfamil Premium has triple health guard. The formula clinically proven to benefit your baby in all three ways: Promotes healthy growth; Improves brain and eye development, helps to build immune system and supports respiratory health.
In the broadcast advertising at issue, an actor portraying a pediatrician said: “I tell Moms, be picky. Look for the baby formula proven to offer three benefits.” The “doctor” then turned to a checklist and marked a check next to the benefits “Growth,” “Brain and Eye” and “Immune System,” and repeated the three benefits as the camera panned to a baby. A bar graph depicting different levels of DHA then appeared on the screen as the actor stated, “With twice the DHA of the leading brand.” The camera then cut to a product shot followed by another shot of the baby. Simultaneously, the actor said, “only Enfamil Premium has triple health guard. It’s a formula clinically proven for your baby’s health [development.]” The commercial concluded with the following voiceover: “Enfamil Premium with triple health guard. Our triple advantage. Learn more at Enfamil.com.”
Taken all together, the challenger argued, the commercial conveys the message that Enfamil Premium is superior to Similac Advance because of its higher DHA content — and that Mead has clinical proof of this fact.
At the outset of NAD’s inquiry, Mead Johnson said that commercial would be discontinued at the end of its broadcast schedule and that any new versions of the commercial would be modified to make the disclosure under the DHA comparison chart will be clearer and more concise; remove the “triple advantage” language and remove the word “only.” The advertiser also asserted that it would modify its print advertising.
Following its review of the evidence, NAD determined that the advertising at issue conveyed the message that that the product was the only infant formula that offered the three advertised benefits, a message that was not supported by the evidence in the record.
NAD further determined that the advertiser’s three-part exclusivity claim was potentially confusing and would remain so regardless of the size and proximity of the accompanying disclosures. NAD recommended that the advertiser discontinue the exclusivity claims in print and Website advertising.
Mead Johnson, in its advertiser’s statement, said it respectfully disagrees with NAD’s determination that an “exclusivity claim incorporating all three proven benefits of Enfamil Premium as formulated in the advertising at issue was overly complicated for consumers.”
“Nonetheless, as noted by NAD in its decision, Mead Johnson already voluntarily has made modifications to its advertising. Mead Johnson continues to support the NAD self-regulatory process and will take the NAD’s recommendations into consideration in future advertising,” the company said.
Hisamitsu America kicks off media campaign for Salonpas brand
TORRANCE, Calif. Hisamitsu America on Thursday kicked off its “Join the Pain Free Movement” initiative, a media campaign to promote its line of Salonpas external pain-relief patches.
“The ‘Join the Pain Free Movement’ will entail public relations activities and a comprehensive advertising campaign that will include television, the Internet and print including [periodicals] People, Oprah and Prevention,” stated Joji Nakayama, Hisamitsu America president. “Hisamitsu will also deploy an extensive social media program that will include Facebook, Twitter and a www.jointhepainfreemovement.com Web site.”
Hisamitsu plans to distribute more than 2 million sample patches throughout the campaign.
“Although analgesic patches are well accepted in Japan and the rest of Asia, this is a new concept for the U.S. consumer,” said Nakayama. “We strongly believe that our products have a huge advantage because we’re the only FDA approved over-the-counter patches.” The Hisamitsu executive stated that his company has done extensive clinical trials and the data is available to complement the products’ marketing program.
FDA commissioner Hamburg invited to testify at Tylenol recall hearing
WASHINGTON The House of Representatives Committee on Oversight and Government Reform chairman Ed Towns, D-N.Y., on Tuesday added Food and Drug Administration commissioner Margaret Hamburg to the list of executives invited to testify during the committee’s upcoming Tylenol recall hearing.
Johnson & Johnson chairman and CEO Bill Wildon has also been invited to testify.
The committee plans to hold the hearing May 27 at 10 a.m.